Citations

Clear

448 citation(s) found for "Ja, Fields".

A fast GPU‐accelerated Monte Carlo engine for calculation of MLC‐collimated electron fields
Brost, Eric E., Tseung, H. Wan Chan, Antolak, John A. , Brost, Eric

Mayo Clinic

Medical Physics | August 20, 2022 | Volume: 50 | Issue: 1 | Pages: 600-618

10.1002/mp.15938 | PMID 35986907 Get It

AbstractBackgroundAlthough intensity‐modulated radiation therapy and volumetric arc therapy have revolutionized photon external beam therapies, the technological advances associated with electron beam therapy have fallen behind. Modern linear accelerators contain technologies that would allow for more advanced forms of electron treatments, such as beam collimation, using the conventional photon multi‐leaf collimator (MLC); however, no commercial solutions exist that calculate dose from such beam delivery modes. Additionally, for clinical adoption to occur, dose calculation times would need to be on par with that of modern dose calculation algorithms.PurposeThis work developed a graphics processing unit (GPU)‐accelerated Monte Carlo (MC) engine incorporating the Varian TrueBeam linac head geometry for a rapid calculation of electron beams collimated using the conventional photon MLC.MethodsA compute unified device architecture framework was created for the following: (1) transport of electrons and photons through the linac head geometry, considering multiple scattering, Bremsstrahlung, Møller, Compton, and pair production interactions; (2) electron and photon propagation through the CT geometry, considering all interactions plus the photoelectric effect; and (3) secondary particle cascades through the linac head and within the CT geometry. The linac head collimating geometry was modeled according to the specifications provided by the vendor, who also provided phase‐space files. The MC was benchmarked against EGSnrc/DOSXYZnrc/GEANT by simulating individual interactions with simple geometries, pencil, and square beam dose calculations in various phantoms. MC‐calculated dose distributions for MLC and jaw‐collimated electron fields were compared to measurements in a water phantom and with radiochromic film.ResultsPencil and square beam dose distributions are in good agreement with DOSXYZnrc. Angular and spatial distributions for multiple scattering and secondary particle production in thin slab geometries are in good agreement with EGSnrc and GEANT. Dose profiles for MLC and jaw‐collimated 6–20‐MeV electron beams showed an average absolute difference of 1.1 and 1.9 mm for the FWHM and 80%–20% penumbra from measured profiles. Percent depth doses showed differences of <5% for as compared to measurement. The computation time on an NVIDIA Tesla V100 card was 2.5 min to achieve a dose uncertainty of <1%, which is ∼300 times faster than published results in a similar geometry using a single‐CPU core.ConclusionsThe GPU‐based MC can quickly calculate dose for electron fields collimated using the conventional photon MLC. The fast calculation times will allow for a rapid calculation of electron fields for mixed photon and electron particle therapy.
Optimum Differentiation of Frontotemporal Lobar Degeneration from Alzheimer Disease Achieved with Cross‐Sectional Tau Positron Emission Tomography
Josephs, Keith A. , Tosakulwong, Nirubol , Gatto, Rodolfo G. , Weigand, Stephen D. , Ali, Farwa , Graff‐Radford, Jonathan , Savica, Rodolfo , Schwarz, Christopher G. , Kantarci, Kejal , Fields, Julie A. , Reichard, Ross R., Petersen, Ronald C. , Lowe, Val J. , Whitwell, Jennifer L. , Graff-Radford, Jonathan , Savica, Rodolfo , Schwarz, Christopher G , Kantarci, Kejal , Dickson, Dennis W , Petersen, Ronald C , Whitwell, Jennifer , Whitwell, Jennifer L , Botha, Hugo , Machulda, Mary M. , Senjem, Matthew L. , Boeve, Bradley F. , Jones, David T. , Ramanan, Vijay K. , Dickson, Dennis W. , Jack, Clifford R.

Mayo Clinic

Annals of Neurology | August 15, 2022 | Volume: 92 | Issue: 6 | Pages: 1016-1029

10.1002/ana.26479 | PMID 36054427 Get It

ObjectiveThis study was undertaken to assess cross‐sectional and longitudinal [18F]‐flortaucipir positron emission tomography (PET) uptake in pathologically confirmed frontotemporal lobar degeneration (FTLD) and to compare FTLD to cases with high and low levels of Alzheimer disease (AD) neuropathologic changes (ADNC).MethodsOne hundred forty‐three participants who had completed at least one flortaucipir PET and had autopsy‐confirmed FTLD (n = 52) or high (n = 58) or low ADNC (n = 33) based on Braak neurofibrillary tangle stages 0–IV versus V–VI were included. Flortaucipir standard uptake value ratios (SUVRs) were calculated for 9 regions of interest (ROIs): an FTLD meta‐ROI, midbrain, globus pallidum, an AD meta‐ROI, entorhinal, inferior temporal, orbitofrontal, precentral, and medial parietal. Linear mixed effects models were used to compare mean baseline SUVRs and annual rate of change in SUVR by group. Sensitivity and specificity to distinguish FTLD from high and low ADNC were calculated.ResultsBaseline uptake in the FTLD meta‐ROI, midbrain, and globus pallidus was greater in FTLD than high and low ADNC. No region showed a greater rate of flortaucipir accumulation in FTLD. Baseline uptake in the AD‐related regions and orbitofrontal and precentral cortices was greater in high ADNC, and all showed greater rates of accumulation compared to FTLD. Baseline differences were superior to longitudinal rates in differentiating FTLD from high and low ADNC. A simple baseline metric of midbrain/inferior temporal ratio of flortaucipir uptake provided good to excellent differentiation between FTLD and high and low ADNC (sensitivities/specificities = 94%/95% and 71%/70%).InterpretationThere are cross‐sectional and longitudinal differences in flortaucipir uptake between FTLD and high and low ADNC. However, optimum differentiation between FTLD and ADNC was achieved with baseline uptake rather than longitudinal rates. ANN NEUROL 2022;92:1016–1029
CLRM-10 METIS (EF-25): A PIVOTAL, RANDOMIZED CONTROLLED STUDY OF TUMOR TREATING FIELDS IN PATIENTS WITH 1–10 BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER
Brown, Paul D. , Gondi, Vinai , Ahluwalia, Manmeet S. , Ahluwalia, Manmeet S , Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology Advances | August 5, 2022 | Volume: 4 | Issue: Supplement_1 | Pages: i8-i8

10.1093/noajnl/vdac078.030 Get It

Abstract BACKGROUND Tumor Treating Fields (TTFields) are electric fields that disrupt cancer cell division. TTFields treatment showed efficacy in preclinical non-small cell lung cancer (NSCLC) models. Furthermore, TTFields therapy improved survival with a tolerable safety profile in patients with glioblastoma. The objective of the pivotal METIS trial [NCT02831959] is to evaluate the efficacy and safety of TTFields therapy in NSCLC patients with brain metastases. METHODS NSCLC patients (N=270) with 1–10 brain metastases will be randomized 1:1 to stereotactic radiosurgery (SRS) followed by continuous TTFields therapy using NovoTTF-200M (150 kHz, recommended &gt;18 h/day) with best standard of care (BSC) or SRS followed by BSC alone. Follow-ups will be conducted every 2 months until second intracranial progression. Key inclusion criteria are: Karnofsky Performance Status ≥70, new diagnosis of 1 inoperable or 2–10 supra- and/or infratentorial brain metastases from NSCLC amenable to SRS, and optimal therapy for extracranial disease. Key exclusion criteria are: prior whole brain radiotherapy, single operable, or recurrent brain metastases. Primary endpoint is time to first intracranial progression. Secondary endpoints include time to neurocognitive failure, overall survival, radiological response rate (RANO-BM and RECIST V1.1), quality of life, adverse events, time to first/second intracranial progression for patients with 1–4 and 5–10 brain metastases, bi-monthly intracranial progression rate from 2–12 months, and time to second intracranial and distant progression. The study is powered at 80% (2-sided alpha of 0.05) to detect a hazard ratio of 0.57. In July 2021, an independent Data Monitoring Committee (DMC) reviewed the study data and recommended continuation as planned. The trial is currently recruiting at 92 sites in North America, Europe, Israel, mainland China and Hong Kong.
A novel computer adaptive word list memory test optimized for remote assessment: Psychometric properties and associations with neurodegenerative biomarkers in older women without dementia
Stricker, John L. , Karstens, Aimee J. , Geske, Jennifer R. , Fields, Julie A. , Hassenstab, Jason , Tosakulwong, Nirubol , Wiste, Heather J. , Jack, Clifford R. , Kantarci, Kejal , Stricker, Nikki H. , Jack, Clifford R , Kantarci, Kejal , Hassenstab, Jason , Geske, Jennifer , Karstens, Aimee James , Schwarz, Christopher G. , Mielke, Michelle M.

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | March 9, 2022 | Volume: 14 | Issue: 1 | Pages: No page available

10.1002/dad2.12299 | PMID 35280963 Get It

AbstractIntroductionThis study established the psychometric properties and preliminary validity of the Stricker Learning Span (SLS), a novel computer adaptive word list memory test designed for remote assessment and optimized for smartphone use.MethodsWomen enrolled in the Mayo Clinic Specialized Center of Research Excellence (SCORE) were recruited via e‐mail or phone to complete two remote cognitive testing sessions. Convergent validity was assessed through correlation with previously administered in‐person neuropsychological tests (n = 96, ages 55–79) and criterion validity through associations with magnetic resonance imaging measures of neurodegeneration sensitive to Alzheimer's disease (n = 47).ResultsSLS performance significantly correlated with the Auditory Verbal Learning Test and measures of neurodegeneration (temporal meta‐regions of interest and entorhinal cortical thickness, adjusting for age and education). Test–retest reliabilities across two sessions were 0.71–0.76 (two‐way mixed intraclass correlation coefficients).DiscussionThe SLS is a valid and reliable self‐administered memory test that shows promise for remote assessment of aging and neurodegenerative disorders.
Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies
Chen, Qin , Przybelski, Scott A. , Senjem, Matthew L. , Lesnick, Timothy G. , Graff‐Radford, Jonathan , Savica, Rodolfo , Fields, Julie A. , Jain, Manoj , Graff‐Radford, Neill R., Ferman, Tanis J. , Kremers, Walter K. , Jack, Clifford R. , Petersen, Ronald C. , Lowe, Val J. , Kantarci, Kejal , Graff-Radford, Jonathan , Savica, Rodolfo , Kantarci, Kejal , Jack, Clifford R , Senjem, Matthew L , Ferman, Tanis J , Kremers, Walter K , Schwarz, Christopher G. , Botha, Hugo , Knopman, David S. , Jones, David T. , Graff‐Radford, Neill R. , Boeve, Bradley F.

Mayo Clinic

Movement Disorders | March 9, 2022 | Volume: 37 | Issue: 6 | Pages: 1256-1264

10.1002/mds.28973 | PMID 35261094 Get It

ABSTRACT Background and Objective Patients with dementia with Lewy bodies (DLB) may have overlapping Alzheimer's disease pathology. We investigated the longitudinal rate of tau accumulation and its association with neurodegeneration and clinical disease progression in DLB. Methods Consecutive patients with probable DLB (n = 22) from the Mayo Clinic Alzheimer's Disease Research Center and age‐matched and sex‐matched cognitively unimpaired controls (CU; n = 22) with serial magnetic resonance imaging and flortaucipir positron emission tomography scans within an average of 1.6 years were included. Regional annualized rates of flortaucipir uptake standardized uptake value ratios (SUVr) were calculated. Regional annualized rates of cortical volume change were measured with the Tensor Based Morphometry–Syn algorithm. Results The annual increase of flortaucipir SUVr was greater in the middle and superior occipital, fusiform, and inferior parietal cortices in DLB (mean: 0.017, 0.019, 0.019, and 0.015, respectively) compared with the CU (mean: −0.006, −0.009, −0.003, and − 0.005, respectively; P < 0.05). In patients with DLB (but not the CU), a longitudinal increase in flortaucipir SUVr was associated with longitudinal cortical atrophy rates in the lateral occipital and inferior temporoparietal cortices, hippocampus, and the temporal pole as well as a concurrent decline on Mini‐Mental State Examination and Clinical Dementia Rating–Sum of Boxes in the lateral occipital and the fusiform cortices. Conclusions Tau accumulation was faster in DLB compared with the CU, with increased accumulation rates in the lateral occipital and temporoparietal cortices. These increased rates of tau accumulation were associated with neurodegeneration and faster disease progression in DLB. Tau may be a potential treatment target in a subset of patients with DLB. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
Contributing Factors to Low Energy Availability in Female Athletes: A Narrative Review of Energy Availability, Training Demands, Nutrition Barriers, Body Image, and Disordered Eating
Jagim, Andrew R. , Fields, Jennifer B. , Magee, Meghan K., Jones, Margaret T. , Jones, Margaret T , Jagim, Andrew R , Kerksick, Chad M.

Mayo Clinic

Nutrients | February 27, 2022 | Volume: 14 | Issue: 5 | Pages: 986

10.3390/nu14050986 | PMID 35267961 Get It

Relative Energy Deficiency in sport is experiencing remarkable popularity of late, particularly among female athletes. This condition is underpinned by low energy availability, which is a byproduct of high energy expenditure, inadequate energy intake, or a combination of the two. Several contributing factors exist that may predispose an athlete to low energy availability, and therefore a holistic and comprehensive assessment may be required to identify the root causes. The focus of the current narrative review is to discuss the primary contributing factors as well as known risk factors for low energy availability among female athletes to help practitioners increase awareness on the topic and identify future areas of focus.
Cardiac ablation with pulsed electric fields: principles and biophysics
Sugrue, Alan , Munoz, Freddy Del‐Carpio , Killu, Ammar M. , Asirvatham, Samuel J. , Del-Carpio Munoz, Freddy , Asirvatham, Samuel J , Maor, Elad

Mayo Clinic

EP Europace | February 25, 2022 | Volume: 24 | Issue: 8 | Pages: 1213-1222

10.1093/europace/euac033 | PMID 35426908 Get It

Abstract Pulsed electric fields (PEFs) have emerged as an ideal cardiac ablation modality. At present numerous clinical trials in humans are exploring PEF as an ablation strategy for both atrial and ventricular arrhythmias, with early data showing significant promise. As this is a relatively new technology there is limited understanding of its principles and biophysics. Importantly, PEF biophysics and principles are starkly different to current energy modalities (radiofrequency and cryoballoon). Given the relatively novel nature of PEFs, this review aims to provide an understanding of the principles and biophysics of PEF ablation. The goal is to enhance academic research and ultimately enable optimization of ablation parameters to maximize procedure success and minimize risk.
Prkci Regulates Autophagy and Pancreatic Tumorigenesis in Mice
Inman, Kristin S. , Buzhardt, Michele Scotti , Leitges, Michael , Krishna, Murli , Fields, Alan P. , Murray, Nicole R. , Scotti Buzhardt, Michele L , Leitges, Michael , Crawford, Howard C, Liu, Yi Sha , Crawford, Howard C.

Mayo Clinic

Cancers | February 4, 2022 | Volume: 14 | Issue: 3 | Pages: 796

10.3390/cancers14030796 | PMID 35159064 Get It

Protein kinase C iota (PKCι) functions as a bonafide human oncogene in lung and ovarian cancer and is required for KrasG12D-mediated lung cancer initiation and progression. PKCι expression is required for pancreatic cancer cell growth and maintenance of the transformed phenotype; however, nothing is known about the role of PKCι in pancreas development or pancreatic tumorigenesis. In this study, we investigated the effect of pancreas-specific ablation of PKCι expression on pancreatic cellular homeostasis, susceptibility to pancreatitis, and KrasG12D-mediated pancreatic cancer development. Knockout of pancreatic Prkci significantly increased pancreatic immune cell infiltration, acinar cell DNA damage, and apoptosis, but reduced sensitivity to caerulein-induced pancreatitis. Prkci-ablated pancreatic acinar cells exhibited P62 aggregation and a loss of autophagic vesicles. Loss of pancreatic Prkci promoted KrasG12D-mediated pancreatic intraepithelial neoplasia formation but blocked progression to adenocarcinoma, consistent with disruption of autophagy. Our results reveal a novel promotive role for PKCι in pancreatic epithelial cell autophagy and pancreatic cancer progression.
Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration
Kantarci, Kejal , Nedelská, Zuzana , Chen, Qin , Gunter, Jeffrey L. , Przybelski, Scott A. , Lesnick, Timothy G. , Kremers, Walter K. , Fields, Julie A. , Graff‐Radford, Jonathan , Savica, Rodolfo , Lowe, Val J. , Graff‐Radford, Neill R. , Murray, Melissa M., Reichard, R. Ross , Jack, Clifford R. , Petersen, Ronald C. , Ferman, Tanis J. , Graff-Radford, Jonathan , Botha, Hugo , Dickson, Dennis W , Jack, Clifford R , Boeve, Brad , Nedelska, Zuzana , Kantarci, Kejal , Ferman, Tanis J , Kremers, Walter K , Senjem, Matthew L. , Schwarz, Christopher G. , Jones, David T. , Botha, Hugo , Knopman, David S. , Dickson, Dennis W. , Boeve, Bradley F.

Mayo Clinic

Brain Communications | February 3, 2022 | Volume: 4 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcac013 | PMID 35415608 Get It

Abstract Mild cognitive impairment with the core clinical features of dementia with Lewy bodies is recognized as a prodromal stage of dementia with Lewy bodies. Although grey matter atrophy has been demonstrated in prodromal dementia with Lewy bodies, longitudinal rates of atrophy during progression to probable dementia with Lewy bodies are unknown. We investigated the regional patterns of cross-sectional and longitudinal rates of grey matter atrophy in prodromal dementia with Lewy bodies, including those who progressed to probable dementia with Lewy bodies. Patients with mild cognitive impairment with at least one core clinical feature of dementia with Lewy bodies (mean age = 70.5; 95% male), who were enrolled in the Mayo Clinic Alzheimer’s Disease Research Center and followed for at least two clinical evaluations and MRI examinations, were included (n = 56). A cognitively unimpaired control group (n = 112) was matched 2:1 to the patients with mild cognitive impairment by age and sex. Patients either remained stable (n = 28) or progressed to probable dementia with Lewy bodies (n = 28) during a similar follow-up period and pathologic confirmation was available in a subset of cases (n = 18). Cross-sectional and longitudinal rates of grey matter atrophy were assessed using voxel-based and atlas-based region of interest analyses. At baseline, prodromal dementia with Lewy bodies was characterized by atrophy in the nucleus basalis of Meynert both in those who remained stable and those who progressed to probable dementia with Lewy bodies (P &lt; 0.05 false discovery rate corrected). Increase in longitudinal grey matter atrophy rates were widespread, with greatest rates of atrophy observed in the enthorhinal and parahippocampal cortices, temporoparietal association cortices, thalamus and the basal ganglia, in mild cognitive impairment patients who progressed to probable dementia with Lewy bodies at follow-up (P &lt; 0.05 false discovery rate corrected). Rates of inferior temporal atrophy were associated with greater rates of worsening on the clinical dementia rating–sum of boxes. Seventeen of the 18 (94%) autopsied cases had Lewy body disease. Results show that atrophy in the nucleus basalis of Meynert is a feature of prodromal dementia with Lewy bodies regardless of proximity to progression to probable dementia with Lewy bodies. Longitudinally, grey matter atrophy progresses in regions with significant cholinergic innervation, in alignment with clinical disease progression, with widespread and accelerated rates of atrophy in patients who progress to probable dementia with Lewy bodies. Given the prominent neurodegeneration in the cholinergic system, patients with prodromal dementia with Lewy bodies may be candidates for cholinesterase inhibitor treatment.
Diagnostic value of plasma P‐tau217 in frontotemporal dementia spectrum disorders
Heuer, Hilary W. , Toller, Gianina , Thijssen, Elisabeth H. , Proctor, Nicholas K. , Forsberg, Leah K. , Brushaber, Danielle , Ramos, Eliana Marisa , Coppola, Giovanni , Bordelon, Yvette , Dickerson, Brad C., Fagan, Anne M. , Fields, Julie A. , Foroud, Tatiana M., Galasko, Doug, Gavrilova, Ralitza H. , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Graff‐Radford, Jonathan , Grant, Ian , Huey, Edward D. , Kornak, John , Ljubenkov, Peter A. , Lucente, Diane , Mackenzie, Ian R. , Masdeu, Joseph C. , Mendez, Mario F. , Miyagawa, Toji , Onyike, Chiadi U. , Pedraza, Otto , Petrucelli, Leonard , Rademakers, Rosa , Rankin, Katherine P. , Rascovsky, Katya, Ritter, Aaron, Savica, Rodolfo , Staffaroni, Adam M. , Trataglia, Maria Carmela, Weıntraub, Sandra , Rosen, Howard J. , Boxer, Adam L. , Rojas, Julio C. , VandeVrede, Lawren , Appleby, Brian S. , Botha, Hugo , Dickson, Dennis W. , Domoto‐Reilly, Kimiko , Fong, Jamie , Goldman, Jill , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Huang, Eric J. , Irwin, David J. , Jones, David T. , Kantarci, Kejal , Knopman, David S. , Kremers, Walter K. , Lapid, Maria I. , Léger, Gabriel C. , Litvan, Irene , Masdeu, Joseph C , McMillan, Corey T. , Miller, Bruce L. , Pascual, Belén , Rexach, Jessica E. , Roberson, Erik D. , Seeley, William W. , Toga, Arthur W. , Wong, Bonnie , Wszołek, Zbigniew K. , Dage, Jeffrey L. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S4 | Pages: No page available

10.1002/alz.055763 Get It

AbstractBackgroundFrontotemporal dementia spectrum disorders (FTD) display complex neuropathological substrates and poor clinicopathological correlations, which hinders therapy development. Plasma P‐tau217 is an emerging tool to screen for Alzheimer’s disease (AD) pathology and may have diagnostic value in FTD.MethodPlasma P‐tau217 was measured cross‐sectionally by electrochemiluminescence in FTD patients referred to ALLFTD from ARTFL (n = 628, 45.7% female, median age 66 ± 12 years). P‐tau217 differences by baseline phenotype, disease severity and genotype were determined with non‐parametric tests and general linear models. Associations between P‐tau217 and measures of disease severity and neuropsychological performance were determined with linear regressions corrected for age, sex, phenotype and APOE.ResultThe sample included 33% behavioral variant FTD, 23.6% primary progressive aphasia (PPA), 28.5% atypical parkinsonism, 1.6% amnestic dementia (AmDem), 2.8% FTD/motoneuron disease, 3% mild cognitive/behavioral impairment and 7.5% healthy controls. Only 1.6% carried FTD‐causing mutations. P‐tau217 was not related to age (r = 0.034, 95%CI ‐0.03 – 0.12, p = 0.4). Compared to controls (0.18 ± 0.07 pg/mL), P‐tau217 was elevated only in AmDem (0.58 ± 0.9 pg/mL, p = 0.001) and logopenic PPA (lvPPA, 0.71 ± 0.62 pg/mL p < 0.001). P‐tau217 ≥ 0.42 pg/mL effectively discriminated AmDem and lvPPA from all other phenotypes (AUC 0.87, 95%CI 0.77 – 0.96, p = 0.001, 77% sensitivity, 92% specificity). AmDem (60%) and lvPPA (91.7%) had the highest prevalence of high (≥ 0.42 pg/mL) P‐tau217, and the highest prevalence of APOE4 (AmDem 40%, lvPPA 63.6%). APOE4 carriers (0.23 ± 0.22 pg/mL) had higher P‐tau217, than non‐carriers (0.19 ± 0.09 pg/mL), regardless of phenotype (APOE effect p = .002, APOE x phenotype, p = 0.44). P‐tau217 was associated with worse clinical severity, mood, memory and executive function, but not with worse motor symptoms or social cognition.ConclusionWhen FTD is suspected, high plasma P‐tau217 is strongly associated with amnestic dementia and logopenic PPA phenotypes. Pending completion of ongoing neuropathological, CSF and molecular neuroimaging analyses, the data support the use of plasma P‐tau217 to identify atypical AD as a cause or AD as a co‐pathology contributing to FTD clinical presentation.